Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)

Margery, J.; Rivière, F.; Planchard, David; Floch, H. Le; Ferrand, François‐Régis; Mairovitz, A.; Besse, B.; Vaylet, F.; Ruffié, Pierre

doi:10.1016/j.pneumo.2010.07.013

Cited by 10 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once again an interesting response was obtained, with a clinical benefit observed in 20 out of 30 patients (disease control rate, DCR, 66%, PR and SD), both by radiological assessment and reduction of pain. Overall TTP and survival were promising for a second-line setting of patients with advanced mesothelioma, 5.1 and 13.6 months, respectively, considering other similar reports from the literature: a French cohort, where several different drugs were used in second-line for patients affected by mesothelioma, showed 3.8 and 12.2 months, respectively for TTP and OS [21], while in a mono-institutional Italian cohort salvage therapy with gemcitabine-platin combination in second or further line demonstrated 3 and 5.5 months, respectively as TTP and OS [22]. We are aware that our group of patients was selected for good prognostic factors, such as PS, benefit after first-line treatment (SD or RP) and a quite long TTP after the end of first-line treatment; moreover no patient was affected by pure sarcomatoid histotype, considered one of the worst prognostic factors [23,24].…”

Section: Discussionmentioning

confidence: 64%

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

et al. 2012

View full text Add to dashboard Cite

BackgroundAlthough first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment.MethodsWe retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment.ResultsOverall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively.ConclusionsIn our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.

show abstract